Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
Breast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demons...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5843244?pdf=render |
id |
doaj-7e723c869748445d875360ff291d3f23 |
---|---|
record_format |
Article |
spelling |
doaj-7e723c869748445d875360ff291d3f232020-11-24T21:46:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019391810.1371/journal.pone.0193918Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.Chhanda BoseSanjay AwasthiRajendra SharmaHelen BenešMartin Hauer-JensenMarjan BoermaSharda P SinghBreast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demonstrated in a mouse model that sulforaphane (SFN), an isothiocyanate isolated from cruciferous vegetables, protects the heart from DOX-induced toxicity and damage. However, the effects of SFN on the chemotherapeutic efficacy of DOX in breast cancer are not known. Present studies were designed to investigate whether SFN alters the effects of DOX on breast cancer regression while also acting as a cardioprotective agent. Studies on rat neonatal cardiomyocytes and multiple rat and human breast cancer cell lines revealed that SFN protects cardiac cells but not cancer cells from DOX toxicity. Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly. Additionally, SFN enhanced mitochondrial respiration in the hearts of DOX-treated rats and reduced cardiac oxidative stress caused by DOX, as evidenced by the inhibition of lipid peroxidation, the activation of NF-E2-related factor 2 (Nrf2) and associated antioxidant enzymes. These studies indicate that SFN not only acts synergistically with DOX in cancer regression, but also protects the heart from DOX toxicity through Nrf2 activation and protection of mitochondrial integrity and functions.http://europepmc.org/articles/PMC5843244?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chhanda Bose Sanjay Awasthi Rajendra Sharma Helen Beneš Martin Hauer-Jensen Marjan Boerma Sharda P Singh |
spellingShingle |
Chhanda Bose Sanjay Awasthi Rajendra Sharma Helen Beneš Martin Hauer-Jensen Marjan Boerma Sharda P Singh Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. PLoS ONE |
author_facet |
Chhanda Bose Sanjay Awasthi Rajendra Sharma Helen Beneš Martin Hauer-Jensen Marjan Boerma Sharda P Singh |
author_sort |
Chhanda Bose |
title |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
title_short |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
title_full |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
title_fullStr |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
title_full_unstemmed |
Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
title_sort |
sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
Breast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demonstrated in a mouse model that sulforaphane (SFN), an isothiocyanate isolated from cruciferous vegetables, protects the heart from DOX-induced toxicity and damage. However, the effects of SFN on the chemotherapeutic efficacy of DOX in breast cancer are not known. Present studies were designed to investigate whether SFN alters the effects of DOX on breast cancer regression while also acting as a cardioprotective agent. Studies on rat neonatal cardiomyocytes and multiple rat and human breast cancer cell lines revealed that SFN protects cardiac cells but not cancer cells from DOX toxicity. Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly. Additionally, SFN enhanced mitochondrial respiration in the hearts of DOX-treated rats and reduced cardiac oxidative stress caused by DOX, as evidenced by the inhibition of lipid peroxidation, the activation of NF-E2-related factor 2 (Nrf2) and associated antioxidant enzymes. These studies indicate that SFN not only acts synergistically with DOX in cancer regression, but also protects the heart from DOX toxicity through Nrf2 activation and protection of mitochondrial integrity and functions. |
url |
http://europepmc.org/articles/PMC5843244?pdf=render |
work_keys_str_mv |
AT chhandabose sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT sanjayawasthi sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT rajendrasharma sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT helenbenes sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT martinhauerjensen sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT marjanboerma sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel AT shardapsingh sulforaphanepotentiatesanticancereffectsofdoxorubicinandattenuatesitscardiotoxicityinabreastcancermodel |
_version_ |
1725900407521148928 |